Last reviewed · How we verify
Testosterone Gel Wolff
Testosterone Gel Wolff is a androgen Small molecule drug developed by University Hospital Muenster. It is currently in Phase 3 development for Treatment of hypogonadism in men.
Testosterone gel increases testosterone levels in the body.
Testosterone Gel Wolff is a testosterone gel used to treat hypogonadism, a condition where the body does not produce enough testosterone. It works by acting as an androgen receptor agonist, binding to the androgen receptor to mimic the effects of natural testosterone.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Testosterone Gel Wolff |
|---|---|
| Sponsor | University Hospital Muenster |
| Drug class | androgen |
| Target | androgen receptor |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | Phase 3 |
Mechanism of action
Testosterone is an androgen hormone that plays a key role in the development and maintenance of male reproductive tissues and secondary sexual characteristics. By increasing testosterone levels, testosterone gel can help alleviate symptoms of hypogonadism, such as low libido, fatigue, and decreased muscle mass.
Approved indications
- Treatment of hypogonadism in men
Common side effects
- Skin irritation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Testosterone Gel Wolff CI brief — competitive landscape report
- Testosterone Gel Wolff updates RSS · CI watch RSS
- University Hospital Muenster portfolio CI
Frequently asked questions about Testosterone Gel Wolff
What is Testosterone Gel Wolff?
How does Testosterone Gel Wolff work?
What is Testosterone Gel Wolff used for?
Who makes Testosterone Gel Wolff?
What drug class is Testosterone Gel Wolff in?
What development phase is Testosterone Gel Wolff in?
What are the side effects of Testosterone Gel Wolff?
What does Testosterone Gel Wolff target?
Related
- Drug class: All androgen drugs
- Target: All drugs targeting androgen receptor
- Manufacturer: University Hospital Muenster — full pipeline
- Therapeutic area: All drugs in Urology
- Indication: Drugs for Treatment of hypogonadism in men
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing